Approved indications: Vemlidy is FDA-approved to treat chronic hepatitis B virus (HBV) infection in adults and in pediatric patients 6 years of age and older who weigh at least 25 kg and have compensated (stable) liver disease.

Off-label uses: Clinicians may use tenofovir alafenamide (the active ingredient in Vemlidy) in some high-risk HBV settings, such as preventing HBV reactivation in patients receiving strong immunosuppressive therapy, but these uses rely largely on extrapolation from chronic hepatitis B data rather than specific FDA-approved indications.

Efficacy expectations:

• HBV DNA (viral load) commonly begins to fall within the first few months of therapy, and many patients achieve very low or undetectable viral levels over 6–12 months or longer of continuous treatment.
• Liver enzyme tests, such as ALT, often move toward the normal range as liver inflammation improves, and long-term suppression of the virus helps reduce the risk of cirrhosis, liver failure, and liver cancer, although complete loss of hepatitis B surface antigen (HBsAg) remains uncommon.
• Compared with other first-line oral HBV drugs like tenofovir disoproxil fumarate and entecavir, Vemlidy offers similar or superior viral suppression with a more favorable profile for kidney function and bone mineral density, making it a preferred option for many patients needing prolonged therapy.

Typical dosing: For adults and for children 6 years and older who weigh at least 25 kg, the recommended dose is one 25 mg tablet taken by mouth once daily with food.

How to take it: Take Vemlidy at about the same time each day with a meal or snack, swallow the tablet whole (without crushing or chewing unless your prescriber advises otherwise), and do not stop the medicine on your own because this can cause a dangerous flare of hepatitis B.

Special dosing instructions:

• No dose adjustment is needed for most patients with mild, moderate, or severe kidney impairment, or for those on chronic hemodialysis, although dialysis patients usually take the dose after their dialysis session.
• Vemlidy is not recommended for people with end-stage kidney disease who are not on chronic hemodialysis, or for those with decompensated (Child-Pugh B or C) liver disease.
• Before starting therapy, patients should be tested for HIV infection, and baseline kidney function should be checked, with periodic monitoring during treatment.

Missed dose and overdose:

• If you miss a dose and remember on the same day, take it as soon as you remember; if it is almost time for your next dose, skip the missed tablet and resume your regular schedule without taking two doses at once.
• In case of overdose, seek emergency medical attention or contact a poison control center immediately so that kidney and liver function and other vital signs can be monitored and treated as needed.

Common side effects:

• Headache, stomach discomfort or abdominal pain, nausea, diarrhea, cough, back or joint pain, fatigue, and indigestion are among the most frequently reported effects and are usually mild to moderate.
• These symptoms typically appear in the first weeks to months of treatment and often improve with continued use.

Serious or rare adverse effects:

• Severe flare of hepatitis B if Vemlidy is stopped suddenly, which can cause serious liver injury or, rarely, liver failure.
• New or worsening kidney problems, including kidney failure, and rare cases of lactic acidosis with severe liver enlargement and fat accumulation.
• Serious liver problems with jaundice (yellow eyes or skin), very dark urine, pale stools, prolonged loss of appetite, nausea or vomiting, or strong upper-abdominal pain.

Warnings and precautions:

• Not recommended in people with decompensated cirrhosis (Child-Pugh B or C); use requires careful monitoring in patients with existing kidney disease.
• Patients who have both hepatitis B and HIV must not take Vemlidy by itself because this can lead to HIV drug resistance; they need a complete HIV regimen that also covers HBV.
• During pregnancy and breastfeeding, the benefits of HBV control should be weighed against limited but reassuring safety data; decisions are individualized in consultation with the clinician.
• Safety and effectiveness are established only in adults and in children 6 years and older who weigh at least 25 kg.

Relative safety versus other options: Compared with tenofovir disoproxil fumarate, Vemlidy generally has less impact on kidney function and bone mineral density while maintaining strong antiviral activity, and overall discontinuation due to side effects is uncommon.

Side-effect reporting and safety updates: Patients can report suspected side effects to the FDA MedWatch program (online or by calling 1-800-FDA-1088), and new safety information is posted through FDA communications and the manufacturer’s website.

Major drug interactions:

• Medicines that strongly induce certain transport proteins and enzymes—such as rifampin, rifabutin, rifapentine, carbamazepine, oxcarbazepine, phenytoin, phenobarbital, or St. John’s wort—can lower Vemlidy levels and are generally not recommended because they may reduce antiviral effectiveness.
• Drugs that impair kidney function or compete for kidney tubular secretion (for example, high-dose or multiple nonsteroidal anti-inflammatory drugs, some antivirals, and certain antibiotics) may increase tenofovir exposure and the risk of kidney side effects when used with Vemlidy.

OTC medicines, supplements, food, and alcohol:

• Always tell your healthcare provider about over-the-counter medicines and supplements; avoid herbal products like St. John’s wort that can interfere with Vemlidy levels.
• Vemlidy should be taken with food to ensure good absorption, but there are no specific restrictions on food types.
• Because alcohol can further injure a hepatitis B–affected liver, limiting or avoiding alcohol is strongly advised.

Conditions and co-medications requiring caution:

• Chronic kidney disease, a history of kidney problems, or concurrent use of other nephrotoxic drugs warrants closer monitoring or alternative choices.
• Decompensated liver disease usually requires other HBV treatment approaches, as Vemlidy is not recommended in this setting.
• Known or suspected HIV infection must be addressed with a full HIV regimen that includes appropriate HBV-active agents; Vemlidy alone should not be used to treat HIV.

Monitoring needs: During therapy, clinicians typically monitor HBV DNA levels and liver enzymes, assess overall liver function, and regularly check kidney function tests (serum creatinine, estimated creatinine clearance, urine protein and glucose, and in some cases serum phosphorus); bone health may be assessed in patients at higher risk for osteoporosis or fractures.

Q: Does Vemlidy cure hepatitis B?
A: Vemlidy usually does not eradicate hepatitis B completely, but it suppresses the virus to very low levels, which helps protect the liver and reduce the risk of long-term complications.

Q: How long will I need to take Vemlidy?
A: Many people take Vemlidy for years, and sometimes indefinitely, with the decision to continue or stop based on liver status, viral levels, and specialist guidance.

Q: What happens if I stop taking Vemlidy suddenly?
A: Stopping Vemlidy abruptly can cause a serious flare or sudden worsening of hepatitis B, so any change in treatment should be done only under close medical supervision with follow-up blood tests.

Q: Can I drink alcohol while taking Vemlidy?
A: Alcohol adds extra stress to the liver, so it is best to limit or avoid drinking while on Vemlidy, especially if you already have liver damage.

Q: Is Vemlidy safe during pregnancy or breastfeeding?
A: Available data do not show a major birth-defect signal, but experience is still limited and the medicine can enter breast milk, so the risks and benefits should be carefully discussed with a clinician if you are pregnant, planning pregnancy, or breastfeeding.

Storage:

• Store Vemlidy tablets at room temperature below 86°F (30°C) in the original, tightly closed bottle with the desiccant, protected from moisture.
• Keep the bottle out of reach of children and pets and avoid storing it in the bathroom or other very humid places.

Disposal:

• Do not flush Vemlidy down the toilet or pour it into a drain unless you are specifically told to do so.
• If possible, use a community drug take-back program, or follow your pharmacist’s or local waste authority’s instructions for safely discarding unused or expired tablets in household trash.